Baird raised the firm’s price target on Iqvia (IQV) to $196 from $159 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- IQVIA Holdings: Balancing Growth in TAS with R&DS Challenges and Economic Pressures Warrants Hold Rating
- IQVIA Holdings: Strong Performance, Growth Potential, and Competitive Advantages Justify Buy Rating and Increased Price Target
- Iqvia price target raised to $185 from $165 at Barclays
- Positive Outlook on IQVIA Holdings Amid Strong Q2 Performance and Competitive Positioning
- Strategic Positioning and Growth in Biotech: Justifying IQVIA Holdings’ Buy Rating